Executive Summary
This BSE Pharma stream covers five filings dated 2026-10-22, all administrative in nature: no financial results, period-over-period figures, insider transactions, capital allocation actions, M&A terms, or forward guidance are disclosed in any of them. Mankind Pharma accounts for three filings (an earnings call time change from 6:00 P.M. to 5:00 P.M.
IST on October 26, 2026, a repeat of that notice, and an in-person Mumbai analyst meet on October 27 that includes leadership of Armed Cell Therapeutics). Divi's Laboratories and IPCA Laboratories filed board-meeting and trading-window notices ahead of their Q2/H1 FY27 results on November 7 and November 5, 2026 respectively. The enriched-data fields requested (YoY/QoQ comparisons, guidance, insider activity) are therefore empty for this batch, so no quantitative cross-company comparison is possible. The actionable takeaway is calendar-driven: the results season for these names opens within two weeks, trading windows are closed for insiders across Divi's and IPCA, and the Mankind call and meet are the near-term information events.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 21, 2026.
Investment Signals (4)
- Mankind Pharma ↓ (NEUTRAL)▲
Earnings call for Q2/H1 FY27 moved earlier to 5:00 P.M. IST on Oct 26, 2026; no results or guidance disclosed in the notice, so signal is informational only
- Mankind Pharma ↓ (NEUTRAL)▲
Institutional meet in Mumbai on Oct 27, 2026 with ACTx leadership present; management engagement with the cell therapy unit may bring commentary on its strategic positioning, not yet quantified
- Divi's Laboratories ↓ (NEUTRAL)▲
Board meeting on Nov 7, 2026 to approve Q2/H1 FY27 results; trading window closed Oct 1 to Nov 9, 2026, meaning insider transaction activity is restricted and absence of trades should not be read as a signal
- IPCA Laboratories ↓ (NEUTRAL)▲
Board meeting on Nov 5, 2026 for standalone and consolidated Q2/H1 FY27 results; trading window closed Oct 1 to Nov 7, 2026, the earliest of the reported results dates in this batch
Risk Flags (3)
- Mankind Pharma/Event Timing↓ [MODERATE RISK]▼
Earnings call time was changed on short notice citing unavoidable circumstances, with a second filing repeating the same change; investors should confirm the revised link and time before the call to avoid missing commentary
- Divi's Laboratories/Information Gap↓ [LOW RISK]▼
Trading window closed from Oct 1, 2026 until Nov 9, 2026 limits insider transactions, so no insider sentiment read is available ahead of results
- IPCA Laboratories/Information Gap↓ [LOW RISK]▼
Insider trading window closed from Oct 1 to Nov 7, 2026; no insider or pledge data is available in this batch to judge management conviction
Opportunities (4)
- Mankind Pharma/Q2 FY27 Earnings Call↓ (OPPORTUNITY)◆
Call on Oct 26, 2026 at 5:00 P.M. IST is the first formal read on H1 FY27 performance from this batch, providing an entry point to assess margins and guidance before the wider results cycle
- Mankind Pharma/ACTx Cell Therapy Exposure↓ (OPPORTUNITY)◆
Presence of Armed Cell Therapeutics leadership at the Oct 27 Mumbai meet signals the company is putting the cell therapy subsidiary in front of institutions, which may prompt disclosure of its scale, pipeline, or funding needs
- Divi's Laboratories/Results Catalyst↓ (OPPORTUNITY)◆
Q2/H1 FY27 results board meeting on Nov 7, 2026 is a defined event date for re-rating or estimate revisions once numbers are published
- IPCA Laboratories/Results Catalyst↓ (OPPORTUNITY)◆
Q2/H1 FY27 results on Nov 5, 2026, the earliest scheduled result in this stream, offers a near-term read on the sector before Divi's
Sector Themes (2)
- Results Season Calendar Clustering (NEUTRAL)◆
Divi's (Nov 7), IPCA (Nov 5) and Mankind (Oct 26 call) all sit within a roughly two-week window, with trading windows closed across the group, so the period is dominated by scheduled disclosure rather than insider-driven moves
- Standardized SEBI Disclosure Practice (NEUTRAL)◆
All five filings use the Reg 29/30/51 disclosure framework and the 48-hour post-results trading window convention, indicating routine compliance rather than any idiosyncratic event
Watch List (5)
-
Revised to 5:00 P.M. IST on Oct 26, 2026; watch H1 FY27 margins, guidance and any ACTx commentary
-
Oct 27, 2026; watch for ACTx disclosures on cell therapy scale, pipeline or funding
-
Board meeting Nov 5, 2026; watch standalone and consolidated revenue, margin and any trading-window reopening on Nov 7
-
Board meeting Nov 7, 2026; watch H1 margin trajectory and trading-window reopening on Nov 9
- Trading Window Reopenings👁
IPCA reopens Nov 7 and Divi's Nov 9, 2026; insider transaction filings after those dates are the next sentiment signal in this stream
Filing Analyses
(5)
22-10-2026
Mankind Pharma Limited has rescheduled its Earnings Conference Call for Q2 and H1 FY27 from Monday, October 26, 2026 at 6:00 P.M. (IST) to 5:00 P.M. (IST) on the same date, citing unavoidable circumstances. All other call details remain unchanged. This is a logistical update with no financial results disclosed in the filing.
- · Original earnings call time was 6:00 P.M. (IST); revised time is 5:00 P.M. (IST), an earlier start by one hour
- · This rescheduling is a continuation of an earlier intimation dated October 12, 2026
- · Filing made under Regulations 30 and 51 of SEBI Listing Obligations and Disclosure Requirements, 2015
- · Scrip Code 543904 / Symbol MANKIND
22-10-2026
Mankind Pharma Limited has intimated under Regulations 30 and 51 of the SEBI Listing Regulations that it will host an in-person Analyst / Institutional Investors' Meet in Mumbai on October 27, 2026, with senior management and leadership of Armed Cell Therapeutics (ACTx) in attendance. The schedule is subject to change, and the filing contains no financial results or quantitative performance data.
- · Meet date: October 27, 2026; format: In-person (Group); location: Mumbai
- · Participation includes leadership team of Armed Cell Therapeutics (ACTx), a cell therapy-related entity
- · Scrip code 543904, symbol MANKIND
22-10-2026
Divi's Laboratories Limited has intimated that its Board of Directors will meet on Saturday, November 07, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's trading window for dealing in its securities has been closed from October 01, 2026, and will remain closed until November 09, 2026 (48 hours after the results declaration).
- · Filing is made under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- · Trading Symbol: DIVISLAB; Scrip Code: 532488
- · Trading window closure was previously intimated to exchanges on September 30, 2026
22-10-2026
Mankind Pharma Limited has rescheduled its Earnings Conference Call for Q2 and H1 FY27 from 6:00 P.M. to 5:00 P.M. (IST) on Monday, October 26, 2026, due to unavoidable circumstances. All other call details remain unchanged, and the company has issued the notice under Regulations 30 and 51 of the SEBI Listing Regulations.
- · Original call time was 6:00 P.M. (IST) on October 26, 2026; revised time is 5:00 P.M. (IST) on the same date
- · This notice follows an earlier intimation dated October 12, 2026 regarding the call schedule
- · Call link and other details were previously communicated and remain unchanged
22-10-2026
IPCA Laboratories Limited has notified the stock exchanges (BSE and NSE) that its Board of Directors will meet on Thursday, 5 November 2026 to consider and take on record the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026. The company has also confirmed that the trading window for insiders remains closed from 1 October 2026 until 48 hours after the results declaration, i.e., until 7 November 2026.
- · Board meeting date: Thursday, 5 November 2026
- · Trading window closed from 1 October 2026 until 7 November 2026 (48 hours after results declaration)
- · Results covered: Standalone and Consolidated Unaudited Financial Results for Q2 and H1 FY ended 30 September 2026
- · Disclosure made under SEBI LODR Regulations 29 and 47 and SEBI (Prohibition of Insider Trading) Regulations, 2015
- · Trading window closure was previously intimated to exchanges via letter dated 22 September 2026
Get daily alerts with 4 investment signals, 3 risk alerts, 4 opportunities and full AI analysis of all 5 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →October 22, 2026
India Pre-Market Regulatory Roundup — October 22, 2026
India Pre-Market Regulatory Roundup
October 22, 2026
India Quarterly Results BSE NSE Announcements — October 22, 2026
India Quarterly Results BSE NSE Announcements
October 22, 2026
India Upcoming Corporate Actions BSE NSE — October 22, 2026
India Upcoming Corporate Actions BSE NSE
October 22, 2026
India Sector Consolidation Regulatory Filings — October 22, 2026
India Sector Consolidation Regulatory Filings